{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-050174","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2022-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.659771+00:00","generated_at":"2026-06-27T05:37:26.234420+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adagio CEO Tillman Gerngross resigns; COO David Hering appointed interim CEO","bullets":["David Hering appointed interim CEO, effective immediately; will also remain Chief Operating Officer.","Board initiated a formal CEO search for a candidate with commercial-stage experience.","Outgoing CEO Tillman Gerngross co-founded company, raised over $800M, advanced ADG20 into global pivotal trials for COVID-19.","Hering previously led Pfizer's mRNA global franchise and was President of North America Vaccines."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-050174","json":"https://secwatch.observer/filing/0001193125-22-050174.json","markdown":"https://secwatch.observer/filing/0001193125-22-050174.md","text":"https://secwatch.observer/filing/0001193125-22-050174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522050174/0001193125-22-050174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522050174/d267907d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:37:26.234420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a1a9c9a67","claim":"Tillman U. Gerngross resigned as Chief Executive Officer and President at Invivyd, Inc..","evidence_excerpt":"On February 23, 2022, Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer and President of Adagio Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522050174/0001193125-22-050174-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"d2e5b617cb","claim":"David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..","evidence_excerpt":"Following Dr. Gerngross’s resignation, on February 23, 2022, the Board appointed David Hering to serve as Interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522050174/0001193125-22-050174-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}